Fig. 8: EZH2 as a therapeutic target to enhance immune response.

EZH2 inhibitors block EZH2 mutant-germinal center cells, leading to upregulation of MCH II expression on the surface of lymphoma cells, and enhancing immune regulation by surrounding follicular helper T-cells.